Siste Nytt
BIOGEN IDEC COMPLETES PURCHASE OF FULL RIGHTS AND CONTROL OF TYSABRI®
Pressemelding 03-04-2013 11:30
BIOGEN IDEC’S TECFIDERA™ (DIMETHYL FUMARATE) APPROVED IN US AS A FIRST-LINE ORAL TREATMENT FOR MULTIPLE SCLEROSIS
Pressemelding 03-04-2013 11:24
Offers a Broad Spectrum of Patients with Relapsing Forms of MS an Effective and Convenient Treatment Option - - Reduces Relapses and Disability Progression - - Strengthens Biogen Idec’s Portfolio of Innovative Treatments for People Living with MS -
BIOGEN IDEC ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF PEGINTERFERON BETA-1A IN MULTIPLE SCLEROSIS
Pressemelding 25-01-2013 10:20
- Every Two-Week and Every Four-Week Dosing Demonstrate Significant Reductions in Annualized Relapse Rate – – Secondary Endpoints on Reduction of Disability Progression, Proportion of Patients Who Relapsed and MRI Assessments Also Met – – Positive Results Support Regulatory Submissions –
